StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX)

Analysts at StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Stock Down 6.0 %

Shares of NASDAQ:JAGX opened at $0.30 on Wednesday. The business has a 50-day moving average price of $0.13 and a 200 day moving average price of $0.17. Jaguar Health has a 12-month low of $0.05 and a 12-month high of $1.22. The company has a debt-to-equity ratio of 6.33, a current ratio of 2.00 and a quick ratio of 1.34.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.